Table 1 Characteristic of the included studies in this meta-analysis
Study | Location | Study design | Sample size (n) | Sex (M/F) (n) | Age (yrs) | HBeAg (+/-) (n) | Regimen | Therapy period | Baseline ALT (U/L) | HBV DNA level (Copies/mL) | Detection limit of HBV DNA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  |  |  | LAM+ADV | ETV | LAM+ADV | ETV | LAM + ADV | ETV | LAM+ADV | ETV | LAM+ADV | ETV | LAM+ADV | LAM+ADV | ETV | LAM+ADV | ETV |  |
Yu [22] | China | Cohort | 54 | 50 | 47/7 | 44/6 | 35.8±8.6 | 37.3±9.5 | 36/18 | 36/14 | LAM 100 mg/d + ADV 10 mg/d | 0.5 mg/d | 96 week | 175.2 ± 123.0 | 144.5±106.8 | 6.2±1.3log10 | 6.0±1.7log10 | <300 Copies/mL |
Wang [21] | China | Cohort | 31 | 40 | 28/3 | 34/6 | 31 ± 6.78 | 29.8 ± 6.0 | 11/20 | 15/25 | LAM 100 mg/d + ADV 10 mg/d | 0.5 mg/d | 48 week | 165.58 ± 80.58 | 140.68 ± 67.68 | 1.42*10^6 | 9.04*10^5 | <10^3 Copies/mL |
Wei [25] | China | Cohort | 20 | 22 | 14/6 | 14/8 | 35 ± 6.89 | 37 ± 6.75 | 20/0 | 22/0 | LAM 100 mg/d + ADV 10 mg/d | 0.5 mg/d | 104 week | NA | NA | NA | NA | 5*10^2 Copies/mL |
Zhang [24] | China | RCTS | 35 | 35 | NA | NA | 43 ± 9 | 43 ± 9 | +:35% | +:23% | LAM 100 mg/d + ADV 10 mg/d | 0.5 mg/d | 96 week | 242 ± 112 | 249 ± 100 | 8.0±0.6log10 | 8.1±0.6log10 | <10^3 Copies/mL |
Jayakumar [23] | India | Cohort | 21 | 20 | M:19% | M:16% | 38.86±12.08 | 42.15±17.11 | 10/11 | 15/5 | LAM 100 mg/d+ADV 10 mg/d | 0.5 mg/d | 24 week | 53 (29–163) | 44 (17–151) | 5.71 (4.2-9.5)log10 | 7.69 (4.0-8.5)log10 | <400 Copies/mL |